Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New rapid PSA test could speed up prostate cancer detection

NCT ID NCT00853710

First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 26 times

Summary

This study tested a simple, rapid PSA blood test that gives results in minutes, comparing it to the standard lab PSA test. Researchers enrolled 94 men with prostate cancer or benign prostate disease. The goal was to see if the quick test is accurate enough for screening. If it works well, it could make prostate cancer screening more accessible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centre Rene Huguenin

    Saint-Cloud, 92210, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rapid prostate specific antigen (PSA) assay

What this could lead to

If accurate, this rapid test could make prostate cancer screening faster and simpler, possibly in a doctor's office without sending blood to a lab.

What could go wrong

This is a small, completed validation study, not a treatment trial. The rapid test may not be as accurate as the standard lab test, and results may not apply to all populations.

Conditions

The condition(s) this trial relates to.

neoplasm prostate cancer prostate disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.